The evolution of the empirical management of fever and neutropenia in cancer patients

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. D, 1998, Pages 65-80

  Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; GENTAMICIN; GLYCOPEPTIDE; NETILMICIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; UREIDOPENICILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; CANCER PATIENT; CLINICAL TRIAL; FEVER; HUMAN; INFECTIOUS COMPLICATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; REVIEW;

EID: 0031749504     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_4.65     Document Type: Review

References (84)

1. Hersh, E. M., Bodey, G. P., Nies, B. A. & Freireich, E. J. (1965). Causes of death in acute leukemia. Journal of the American Medical Association 193, 105-9.
2. Hughes, W. T. (1971). Fatal infections in childhood leukemia. American Journal of Diseases of Children 122, 282-7.
3. Levine, A. S., Schimpff, S. C., Graw, R. G. & Young, R. C. (1974). Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Seminars in Hematology 11, 141-202.
4. Chang, H. Y., Rodriguez, V., Narboni, G., Bodey, G. P., Luna, M. A. & Freireich, E. J. (1976). Causes of death in adults with acute leukemia. Medicine 55, 259-68.
5. Feld, R. & Bodey, G. P. (1977). Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39, 1018-25.
6. Pizzo, P. A. & Meyers, J. (1989). Infections in the cancer patient. In Principles and Practice of Oncology (De Vita, V. T., Hellma, S. & Rosenberg, S. A., Eds), pp. 2088-133. Lippincott, Philadelphia, PA.
7. Morittu, L. Earl, H. M., Souhami, R. L., Ash, C. M., Tobias, J. S., Geddes, D. M. et al. (1989). Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. British Journal of Cancer 59, 801-4.
8. Meyers, J. D. & Thomas, E. D. (1988). Infection complicating bone marrow transplantation. In Clinical Approach to Infection in the Compromised Patient, 2nd edn (Rubin, R. H. & Young, L. S., Eds), pp. 525-56. Plenum, New York, NY.
9. Viscoli, C., Boni, L., Etzioni, R., Seidel, K. & Anasetti, C. (1994). Infections in recipients of bone marrow transplant (BMT) from unrelated donors. In Program and Abstracts of the 8th International Symposium on Infections in the Immunocompromised Host. Abstract 39. Davos, Switzerland.
10. Klastersky, J., Zinner, S. H., Calandra, T., Gaya, H., Glauser, M. P., Meunier, F. et al. (1988). Empiric antimicrobial therapy for febrile, granulocytopenic cancer patients: lessons from four EORTC trials. European Journal of Cancer and Clinical Oncology 24, Suppl. 1, S35-45.
11. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I. et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine 325, 164-70.
12. Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B. et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications or cytotoxic chemotherapy. European Journal of Cancer 29A, 319-24.
13. Longo, D. L., Duffey, P. L., DeVita, V. T., Wesley, M. N., Hubbard, S. M. & Young, R. C. (1991). The calculation of actual or received dose intensity: a comparison of published methods. Journal of Clinical Oncology 9, 2042-51.
14. Morstyn, G., Campbell, L., Souza, L. M., Alton, N. K., Keech, J., Green, M. et al. (1988). Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet i, 667-72.
15. Nemunaitis, J., Rabinowe, S. N., Singer, J. W., Bierman, P. J., Vose, J. M., Freedman, A. S. et al. (1991). Recombinant granulocyte-monocyte colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New England Journal of Medicine 324, 1773-8.
16. Anasetti, C., Anderson, G., Appelbaum, F. R., Buckner, C. D., Martin, P. J., Nemunaitis J. et al. (1993). Phase III study of rh-GM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 82, Suppl. 1, Abstract 1799.
17. Roilides, E. & Pizzo, P. A. (1993). Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts. Hematology/Oncology Clinics of North America 7, 841-64.
18. Armstrong, D., Young, L. S., Meyer, R. D. & Blevins, A. H. (1971). Infectious complications of neoplastic disease. Medical Clinics of North America 55, 729-45.
19. Bodey, G. P., Buckley, M., Sathe, Y. S. & Freireich, E. J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64, 328-40.
20. Schimpff, S., Satterlee, W. & Young, V. M. (1971). Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine 284, 1061-7.
21. Klastersky, J. (1986). Concept of empiric therapy with antibiotic combinations. Indications and limits. American Journal of Medicine 80, Suppl. 5C, 2-12.
22. Bow, E. J., Loewen, R., Cheang, M. S. & Schacter, B. (1995). Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases 21, 361-9.
23. Mirro, J., Rao, B. N., Stokes, D. C., Austin, B. A., Kumar, M., Dahl, G. V. et al. (1989). A prospective study of Hickman-Broviac catheters and implantable ports in pediatric oncology patients. Journal of Clinical Oncology 7, 214-22.
24. EORTC International Antimicrobial Therapy Cooperative Group (1993). Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Annals of Internal Medicine 119, 584-93.
25. Klastersky, J., Glauser, M. P. Schimpff, S. C., Zinner, S. H. & Gaya, H. (1986). Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy 29, 263-70.
26. McCabe, W. R. & Jackson, G. G. (1962). Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Archives of Internal Medicine 110, 856-64.
27. EORTC International Antimicrobial Therapy Project Group. (1978). Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. Journal of Infectious Diseases 137, 14-29.
28. Viscoli, C., Bruzzi, P., Castagnola, E., Boni, L., Calandra, T., Gaya, H. et al. (1994). Factors associated with bactaeremia in febrile, granulocytopenic cancer patients. European Journal of Cancer 30A, 430-7.
29. Talcott, J. A., Finberg, R., Mayer, R. J. & Goldman, L. (1988). The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Archives of Internal Medicine 148, 2561-8.
30. Talcott, J. A., Siegel, R. D., Finberg, R. & Goldman, L. (1992). Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology 19, 316-22.
31. Buchanan, G. R. (1993). Approach to the treatment of the febrile cancer patient with low-risk neutropenia. Hematology/Oncology Clinics of North America 7, 919-35.
32. Viscoli, C., Van der Auwera, P. & Meunier, F. (1988). Gram-positive infections in granulocytopenic patients: an important issue? Journal of Antimicrobial Chemotherapy 21, Suppl. C, 149-56.
33. EORTC International Antimicrobial Therapy Cooperative Group. (1983). Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. Journal of Clinical Oncology 1, 597-603.
34. EORTC International Antimicrobial Therapy Cooperative Group (1987). Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. New England Journal of Medicine 317, 1692-8.
35. EORTC International Antimicrobial Therapy Cooperative Group. (1990). Gram-positive bacteraemia in granulocytopenic cancer patients. European Journal of Cancer 26, 569-74.
36. EORTC International Antimicrobial Therapy Cooperative Group & the National Cancer Institute of Canada Clinical Trials Group. (1991). Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. Journal of Infectious Diseases 163, 951-8.
37. EORTC International Antimicrobial Therapy Cooperative Group. (1993). In vitro activity of piperacillin-tazobactam against 365 aerobic bacteria isolated from blood in granulocytopenic cancer patients. In Program and Abstracts of the 18th International Congress of Chemotherapy, Stockholm, 1993. Abstract 380. Scandinavian Society for Antimocrobial Chemotherapy, Stockholm.
38. Cometta, A., Zinner, S., de Bock, R., Calandra, T., Gaya, H., Klastersky, J. et al. (1995). Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 39, 445-52.
39. Cometta, A., Calandra, T., Gaya, H., Zinner, S. H., de Bock, R., Del Favero, A. et al. (1996). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 43, 1108-15.
40. Corey, L. & Spear, P. G. (1986). Infections with herpex simplex viruses. New England Journal of Medicine 314, 749-57.
41. Viscoli, C., Perlino, G. F., Moroni, C., Ferrea, G., Fabbri, A., Haupt, R. et al. (1984). Gram-positive infections in pediatric cancer patients: 84 cases. In Program and Abstracts of the 3rd international Symposium on infections in the Immunocompromised Host. Abstract 136. Toronto, Canada.
42. Pizzo, P. A., Ladisch, S. & Witebsky, F. G. (1978). Alpha-hemolytic streptococci: clinical significance in the cancer patient. Medical and Pediatric Oncology 4, 367-70.
43. Karp, J. E., Merz, W. G., Hendricksen, C., Laughon, B., Redden, T., Bamberger, B. J. et al. (1987). Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 106, 1-7.
44. Castagnola, E., Garaventa, A., Lavagetto, A., Nantron, M., Tasso, L., Venzano, P. et al. (1995). Single-agent bacteremias in neutropenic children after antineoplastic chemotherapy or bone marrow transplantation. 19th International Congress of Chemotherapy. Canadian Journal of Infectious Diseases 6, Suppl. C, Abstract 0490.
45. Hughes, T. W., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
46. Malik, I. A., Abbas, Z. & Karim, M. (1992). Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339, 1092-6.
47. Rains, C. P., Bryson, H. M. & Peters, D. H. (1995). Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49, 577-617.
48. Levison, M. E. (1992). New dosing regimens for aminoglycoside antibiotics. Annals of Internal Medicine 117, 693-4.
49. Viscoli, C., Dudley, M., Ferrea, G., Boni, L., Castagnola, E., Barretta, M. A. et al. (1991). Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. Journal of Antimicrobial Chemotherapy 27, Suppl. C, 113-20.
50. Meunier, F., Van der Auwera, P., Aoun, M., Ibrahim, S. & Tulkens, P. M. (1991). Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. Journal of Antimicrobial Chemotherapy 27, Suppl. C, 129-39.
51. Winston, D. J., Ho, W. G., Bruckner, D. A. & Champlin, R. E. (1991). Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Annals of Internal Medicine 115, 849-59.
52. Pizzo, P. A., Hathorn, J. W., Hiemenz, J., Browne, M., Commers, J., Cotton, D. et al. (1986). A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine 315, 552-8.
53. De Pauw, B. E., Deresinski, S. C., Feld, R., Lane-Allman, E. F. & Donnelly, J. P. (1994). Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Annals of Internal Medicine 120, 834-44.
54. Karp, J. E., Dick, J. D., Angelopulos, C., Charache, P., Green, L., Burke, P. J. et al. (1986). Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. American Journal of Medicine 81, 237-42.
55. Shenep, J. L., Hughes, W. T., Roberson, P. K., Blankenship, K. R., Baker, D. K., Meyer, W. H. et al. (1988). Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. New England Journal of Medicine 319, 1053-8.
56. Del Favero, A., Menichetti, F., Guerciolini, R., Bucaneve, G., Baldelli, F., Aversa, F. et al. (1987). Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrobial Agents and Chemotherapy 31, 1126-9.
57. Rubin, M., Hathorn, J. W., Marshall, D., Gress, J., Steinberg, S. M. & Pizzo, P. A. (1988). Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Annals of Internal Medicine 108, 30-5.
58. Viscoli, C., Moroni, C., Boni, L., Bruzzi, P., Comelli, A., Dini, G. et al. (1991). Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Reviews of Infectious Diseases 13, 397-404.
59. Immunocompromised Host Society Consensus Panel. (1990). The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Journal of Infectious Diseases 161, 397-401.
60. Hughes, W. T., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, C. D. & Young, L. S. (1992). Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clinical Infectious Diseases 15 Suppl. 1, S206-15.
61. Meunier, F., Hughes, W., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, D. et al. (1993). General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. In European Guidelines for the Clinical Evaluation of Anti-Infective Drug Products (Beam, T. R., Gilbert, D. N., Kunin, C. M. & the European Working Party, Eds), pp. 221-7. European Society of Clinical Microbiology and Infectious Disease.
62. Viscoli, C., Bruzzi, P. & Glauser, M. (1995). An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. European Journal of Cancer 31A, 2013-22.
63. Sackett, D. L. & Gent, M. (1979). Controversy in counting and attributing events in clinical trials. New England Journal of Medicine 301, 1410-2.
64. Sackett, D. L. (1983). On some prerequisites for a successful clinical trial. In Clinical Trials: Issues and Approaches (Shapiro, S. H. & Louis, T. A., Eds), pp. 65-79. Marcel Dekker, New York, NY.
65. Sanders, J. W., Powe, N. R. & Moore, R. D. (1991). Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. Journal of Infectious Diseases 164, 907-16.
66. CPMP Working Party on Efficacy of Medicinal Products. Commission of the European Communities. (1990). EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacology and Toxicology 97, 361-72.
67. Meunier, F., Zinner, S. H., Gaya, H., Calandra, T., Viscoli, C., Klastersky, J. et al. (1991). Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrobial Agents and Chemotherapy 35, 873-8.
68. Kunin, C. M. (1993). Resistance to antimicrobial drugs - a worldwide calamity. Annals of Internal Medicine 118, 557-61.
69. Murray, B. E. (1995). What can we do about vancomycin-resistant enterococci? Clinical Infectious Diseases 20, 1134-6.
70. Bochud, P. Y., Eggiman, P., Calandra, T., Van Melle, G., Saghafi, L. & Francioli, P. (1994). Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clinical Infectious Diseases 18, 25-31.
71. Vogelman, B. & Craig, W. A. (1986). Kinetics of antimicrobial activity. Journal of Pediatrics 108, 835-40.
72. Gilbert, D. N. (1991). Once-daily aminoglycoside therapy. Antimicrobial Agents and Chemotherapy 35, 399-405.
73. DiNubile, M. J. (1988). Stopping antibiotic therapy in neutropenic patients. Annals of Internal Medicine 108, 289-92.
74. de Marie, S., van den Broek, P. J., Willemze, R. & van Furth, R. (1993). Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. European Journal of Clinical Microbiology & Infectious Diseases 12, 897-906.
75. Kaplan, A. H., Weber, D. J., Davis, L., Israel, F. & Wells, R. J. (1991). Short courses of antibiotics in selected febrile neutropenic patients. American Journal of the Medical Sciences 302, 353-4.
76. Wiernikoski, J. T., Rothney, M., Dawson, S. & Andrew, M. (1991). Evaluation of a home intravenous antibiotic program in pediatric oncology. American Journal of Pediatric Hematology and Oncology 13, 144-7.
77. Mullen, C. A. & Buchanan, G. R. (1990). Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. Journal of Clinical Oncology 8, 1998-2004.
78. Griffin, T. C. & Buchanan, G. R. (1992). Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. Journal of Pediatrics 121, 28-33.
79. Meropol, N. J., Fox, K. R., Vaughn, D. J. & Zeiber, N. (1994). A pilot study of early hospital discharge in adult patients with fever and neutropenia. European Journal of Cancer 30A, 1595-6.
80. Rubenstein, E. B., Rolston, K., Benjamin, R. S., Loewy, J., Escalante, C., Manzullo, E. et al. (1993). Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71, 3640-6.
81. Martino, P., Girmenia, C., Raccah, R., Micozzi, A., Cimino, G., Sgadari, C. et al. (1992). Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 49, 49-52.
82. Malik, I. A., Khan, W. A., Ariz, Z. & Karim, M. (1994). Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Diseases 19, 522-7.
83. Talcott, J. A., Whalen, A., Clark, J., Rieker, P. P. & Finberg, R. (1994). Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology 12, 107-14.
84. Metz, C. E. (1978). Basic principles of ROC analysis. Seminars in Nuclear Medicine 8, 283-98.